Norgalax
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Norgalax
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Norgalax contains the active ingredient Docusate Sodium 0.12 g in each 10 g micro-enema.
3. PHARMACEUTICAL FORM
Rectal gel.
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
For the symptomatic treatment of constipation whenever an enema is required and for the preparation of the colon and rectum for endoscopic examination.
4.2 Posology and method of administration
Adults: use one micro-enema. If required, a second micro-enema may be used on the same or the next day.
Children: not recommended for children under 12 years old.
Norgalax is to be administered rectally. Remove the protective cap and insert the applicator into the rectum, squeezing gently until the tube is empty. A drop of the gel may be used as a lubricant if required.
4.3 Contraindications
Haemorrhoids, anal fissures, rectocolitis, anal bleeding, abdominal pain, intestinal obstruction, nausea, vomiting, inflammatory bowel disease, ileus and known
4.4 Special warnings and precautions for use
As with all laxatives, Norgalax should not be administered chronically. Prolonged use can precipitate the onset of an atonic nonfunctioning colon and hypokalaemia.
4.5 Interactions with other medicinal products and other forms of interaction
Norgalax may increase the resorption of medicines and is not to be used in combination with hepatotoxic agents.
4.6 Pregnancy and lactation Pregnancy
There are no adequate data from the use of docusate enema or oral docusate in pregnant women. Animal studies with oral docusate are insufficient with respect to effects on pregnancy and embryonic foetal development.
The potential risk for humans is unknown. As minimal systemic absorption cannot be ruled out following rectal application, Norgalax should be used in pregnancy only if the benefits outweigh the risks.
Lactation
It is unknown whether docusate is excreted in human breast milk. Animal studies have shown excretion of docusate and its metabolites in breast milk when administered systemically. A decision on whether to continue/discontinue breastfeeding or continue/discontinue therapy with NORGALAX should be made taking into account the benefit of breast-feeding to the child and the benefit of NORGALAX therapy to the woman.
4.7 Effects on ability to drive and use machines
None known.
4.8. Undesirable Effects
Gastrointestinal disorders: anal burning, rectal pain, rectal bleeding, diarrhoea Skin disorders: urticaria
Hepatic disorders: cases of hepatotoxicity have been reported with oral intake of docusate taken together with other laxatives.
4.9 Overdose
Overdose will lead to excessive purgation which should be treated symptomatically.
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Docusate sodium is an anionic surfactant and used as a faecal softening agent. It is considered to ease constipation by increasing the penetration of fluid into the faeces thereby causing them to soften. Norgalax is usually effective in 5 to 20 minutes.
5.2 Pharmacokinetic properties
Norgalax has a local effect in the rectum. Minimal absorption cannot be ruled out even with a rectal application.
5.3 Preclinical safety data
Non-clinical data reveal no special hazard for humans based on studies of acute
toxicity, repeated dose toxicity and in-vitro genotoxicity. Docusate sodium has been shown to exhibit developmental toxicity in rodents at oral doses that are maternally toxic and sufficiently in excess of the maximum human exposure indicating little relevance to clinical use. High oral doses given during lactation reduced pup weight and survival which was attributed to docusate and its metabolites present in the milk of the dams.
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Glycerol
Sodium carboxymethyl cellulose Purified Water
6.2
Incompatibilities
None known
6.3 Shelf life
3 years
6.4 Special precautions for storage
Do not store above 25°C.
6.5 Nature and contents of container
A polyethylene tube with fixed applicator and a cap closure, containing 10g of gel in pack sizes of 6 and 100 tubes.
6.6 Instructions for use/handling
None.
7 MARKETING AUTHORISATION HOLDER
Norgine Limited,
Norgine House,
Widewater Place,
Moorhall Road,
Harefield,
Uxbridge,
Middlesex,
UB9 6NS,
United Kingdom
8. MARKETING AUTHORISATION NUMBER
PL 00322/0065.
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
18/01/2005
10
DATE OF REVISION OF THE TEXT
21/01/2014